Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Investment Income (2023 - 2024)

Historic Non Operating Investment Income for Spyre Therapeutics (SYRE) over the last 2 years, with Q4 2024 value amounting to -$800000.0.

  • Spyre Therapeutics' Non Operating Investment Income changed N/A to -$800000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$800000.0, marking a year-over-year increase of 9904.31%. This contributed to the annual value of -$20.4 million for FY2024, which is 7554.17% up from last year.
  • Per Spyre Therapeutics' latest filing, its Non Operating Investment Income stood at -$800000.0 for Q4 2024.
  • Over the past 5 years, Spyre Therapeutics' Non Operating Investment Income peaked at -$800000.0 during Q4 2024, and registered a low of -$58.2 million during Q2 2023.